Suppliers / Apisyn Healthcare

Apisyn Healthcare

India 65 employees Updated 9 July 2026

Apisyn Healthcare is an API manufacturer based in India. It holds 6 active US drug master files across a filed portfolio of 5 molecules. Customs aggregates show $1.4M of exports covering 17 molecules to 2 destinations in 2025.

6
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026.

Registered plants

Site FDA FEI
Ahmedabad, India 3035217826

What they file, and where

Molecule Regulators Docs
Linezolid US FDA 2
Apixaban US FDA 1
Methimazole US FDA 1
Rivaroxaban US FDA 1
Sotalol US FDA 1

Also appears on these molecule pages

Scale

Year Revenue Exports Destinations
2025 Not reported $1.4M 2
2024 Not reported $43K 1

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Apisyn Healthcare comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts